Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | OXTR | P30559 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4643814 | 0.86 | BRD4 (0.50) | BRD4AVPR1ATRPA1TRPM8OXTR | |
| SCHEMBL4618452 | 0.82 | BRD4 (0.40) | BRD4AVPR1ATRPA1TRPM8OXTR | |
| SCHEMBL4618519 | 0.81 | MAOB (0.36) | BRD4AVPR1ATRPA1TRPM8OXTR | |
| SCHEMBL4621605 | 0.80 | ALDH1A1 (0.41) | BRD4ALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL4618544 | 0.79 | OXTR (0.36) | BRD4AVPR1ATRPA1TRPM8OXTR | |
| SCHEMBL4619815 | 0.79 | OXTR (0.49) | AVPR1AOXTRALDH1A1MAPTRAB9A | |
| SCHEMBL4621149 | 0.77 | SIGMAR1 (0.45) | BRD4AVPR1ATRPA1TRPM8ALDH1A1 | |
| SCHEMBL8285404 | 0.77 | ADRB1 (0.56) | BRD4AVPR1ATRPA1TRPM8CETP | |
| Hydrochloric Acid SCHEMBL315352 | 0.75 | ADRB1 (0.54) | BRD4AVPR1ATRPA1TRPM8CETP | |
| SCHEMBL4621637 | 0.75 | AVPR1A (0.50) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | claimed |
| EP-1885713-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-02-13 | — | — | EP | claimed |
| WO-2006123242-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-23 | — | — | WO | claimed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| EP-1885713-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123242-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | AVPR1A, AVPR1B, AVPR2 | BRD4 819/4885AVPR1A 1/4885TRPA1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.